ENTRY       D11034            Mixture   Drug
NAME        Insulin glargine and lixisenatide;
            Insulin glargine (genetical recombination) and lixisenatide;
            Soliqua (TN)
PRODUCT     SOLIQUA 100/33 (sanofi-aventis U.S. LLC)
COMPONENT   Insulin glargine [DR:D03250], Lixisenatide [DR:D09729]
CLASS       Antidiabetic agent
             DG01636  Insulin preparation
              DG03229  Combination of insulin analog and GLP-1 receptor agonist
REMARK      Therapeutic category: 3969
            ATC code: A10AE54
            Product: D11034<JP/US>
EFFICACY    Antidiabetic
  DISEASE   Type 2 diabetes mellitus [DS:H00409]
TARGET      INSR (CD220) [HSA:3643] [KO:K04527]
            GLP1R [HSA:2740] [KO:K04581]
  PATHWAY   hsa04910(3643)  Insulin signaling pathway
            hsa04911(2740)  Insulin secretion
            hsa04930(3643)  Type II diabetes mellitus
            hsa04931(3643)  Insulin resistance
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             A ALIMENTARY TRACT AND METABOLISM
              A10 DRUGS USED IN DIABETES
               A10A INSULINS AND ANALOGUES
                A10AE Insulins and analogues for injection, long-acting
                 A10AE54 Insulin glargine and lixisenatide
                  D11034  Insulin glargine and lixisenatide &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Blood Glucose Regulators
              Antidiabetic Combinations
               Insulin Glargine/ Lixisenatide
                D11034  Insulin glargine and lixisenatide
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               396  Antidiabetic agents
                3969  Others
                 D11034  Insulin glargine and lixisenatide
            Drug groups [BR:br08330]
             Antidiabetic agent
              DG01636  Insulin preparation
               DG03229  Combination of insulin analog and GLP-1 receptor agonist
                D11034  Insulin glargine and lixisenatide
            Drug classes [BR:br08332]
             Antidiabetic agent
              DG01636  Insulin preparation
               D11034  Insulin glargine and lixisenatide
            Target-based classification of drugs [BR:br08310]
             G Protein-coupled receptors
              Secretin receptor family
               Glucagon
                GLP1R
                 D11034  Insulin glargine and lixisenatide &lt;JP/US&gt;
             Protein kinases
              Receptor tyrosine kinases (RTK)
               INSR family
                INSR (CD220)
                 D11034  Insulin glargine and lixisenatide &lt;JP/US&gt;
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11034
DBLINKS     PubChem: 350078353
///
